The weight-loss drug Ozempic can help reduce stroke patients' risk of a heart attack or death, a new study says.

Semaglutide, the GLP-1 drug that Novo sells under the brand names Ozempic for diabetes and Wegovy for weight loss, has made ...

Fact checked by Nick Blackmer A recent study found that semaglutide, a GLP-1 weight loss drug, reduced knee pain in people with obesity and knee osteoarthritis.Experts say the reduced knee pain ...

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the risk of heart attack, second strokes and death ...

Powers Health surgical and medical weight-loss services in Hobart and Munster provide tailored support and experts who ...

(NewMediaWire) - November 11, 2024 - DALLAS GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or weight loss, may reduce the ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 ...

Novo Nordisk's stock has dropped to $110 per share, but operational performance remains strong. See why I believe we are at ...

Drugs that belong to the class of GLP-1 receptor agonists could cause muscle loss These drugs reduce appetite and are used ...

SGLT2 diabetes meds like Jardiance or Farxiga do the same, and also decrease risk of a follow-up stroke Originally published ...

U.S. military veterans face racial and ethnic inequities in access to Novo Nordisk's highly in-demand drugs for diabetes and weight loss, according to a review of patient data published on Monday, the ...